04 November 2024
-> PDF Version (PDF, 530KB)
- Strategic partnership formed between inscreenex and Cytion to enhance access to highly customized cell lines for drug discovery and development.
- Leverages complementary strengths: inscreenex’s expertise in generating highly customized and functional cell lines, and Cytion’s global cell banking and distribution capabilities.
- Immediate availability of inscreenex’s stable cells overexpressing in-demand (immuno) oncology drug targets through Cytion’s online catalogue.
- Commitment to future collaborations, with additional joint initiatives and announcements planned.
inscreenex, specialized in creating highly customized and functional cell lines for drug discovery, and Cytion (a registered brand of CLS Cell Lines Service GmbH), a global provider of high-quality cell banking and distribution services, today announced a strategic collaboration aimed at accelerating drug discovery efforts worldwide. This partnership combines the complementary strengths of both companies to provide researchers and pharmaceutical organizations with easy and quick access to highly customized cell lines.
Under this collaboration, inscreenex and Cytion will work together to leverage their respective expertise. inscreenex brings its innovative technologies in developing customized and functional cell lines, which are critical tools in all stages of drug discovery. Cytion contributes its trusted cell banking capabilities, ensuring high-quality storage and rapid global distribution, providing commercial customers with easy access to essential cell lines.
The first initiative of this partnership is the distribution of inscreenex’s stable cells, which overexpress in-demand drug targets for (immuno) oncology research. These cells are now easily available worldwide through Cytion’s online catalogue, enabling researchers to accelerate their work with reliable and high-quality cell lines.
Both companies are committed to ongoing collaboration, with plans to introduce additional joint initiatives and product offerings in the near future.
Executive Quotes:
„We are excited to collaborate with Cytion to expand the reach of our customized cell lines,“ said Dr. Roland Schucht, CEO of inscreenex. „By relying on Cytions trusted cell banking and global distribution capabilities, we can focus on what we can do best: generate useful cells that move research forward.“
„Partnering with inscreenex allows us to offer our customers access to some very unique cell lines,“ said Jonathan Steubing, CEO of Cytion. „This collaboration underscores our commitment to supporting the scientific community with high-quality cell lines and efficient delivery services, ultimately accelerating the development of new therapies.“
About inscreenex:
inscreenex is a biotechnology company specializing in the generation of highly customized and functional cell lines for drug discovery and development. Utilizing advanced technologies, inscreenex provides researchers with tailored cell line solutions that enable more accurate and efficient drug screening processes. For more information, visit www.inscreenex.com.
About Cytion (a registered brand of CLS Cell Lines Service GmbH):
Cytion is a leading provider of high-quality cell banking services, offering rapid delivery times and easy access to a wide range of cell lines for commercial customers worldwide. With a focus on quality and reliability, Cytion supports the global scientific community by ensuring that essential cell lines are readily available for research and development. For more information, visit www.cytion.com.
For More Information:
To learn more visit inscreenex.com or cytion.com and to access the newly available overexpression cells, please visit Cytion’s online catalogue at https://www.cytion.com/cells-and-cell-lines.